BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
Early clinical data show promising efficacy — Prometimic reported ORRs of ~85% in first-line small cell lung cancer and ~70% in triple-negative breast cancer, and Gotistobart's unblinded stage-1 analysis showed a 54% reduction in risk of death versus docetaxel. Financial runway of more than $17 billion in cash and securities will be used primarily to fund organic late-stage development (supported by COVID vaccine revenues), with inorganic deals a secondary priority. Interested in BioNTech SE Sponsored ADR? Here are five stocks we like better. 4 Reasons Pfizer Could Be a Value Play You Can't Miss BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-stage development. Chief Executive Officer Ugur Sahin said BioNTech's long-term vision r
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR Newswire
- BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026GlobeNewswire
- BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.MarketBeat
- Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]Yahoo! Finance
- BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People OfficerGlobeNewswire
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 2/12/26 - Form 144
- 1/28/26 - Form 6-K
- 1/14/26 - Form 6-K
- BNTX's page on the SEC website